Global S&T Development Trend Analysis Platform of Resources and Environment
Moderna COVID-19 vaccine authorised by UK medicines regulator | |
admin | |
2021-01-08 | |
发布年 | 2021 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 ; 资源环境 |
正文(英文) | Moderna COVID-19 vaccine authorised by UK medicines regulatorThe Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the Moderna vaccine after an extensive analysis of the vaccine’s safety, quality and effectiveness.
The Moderna COVID-19 vaccine has been authorised for use by the medicines regulator. The Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the recommendation of the Commission on Human Medicines and authorised the Moderna vaccine following months of rigorous clinical trials involving tens of thousands of people and an extensive analysis of the vaccine’s safety, quality and effectiveness. The vaccine is 94% effective in preventing disease, including in the elderly. The government was one of the first to sign an agreement with the company to supply the vaccine on behalf of the UK, Crown Dependencies and Overseas Territories. The government has agreed to purchase an additional 10 million doses of the Moderna vaccine on top of its previous order of 7 million, taking the total to 17 million. As agreed when the UK originally pre-ordered the vaccine, supplies will begin to be delivered to the UK from spring once Moderna expands its production capability. The vaccine will be available for free and the government is working with the devolved administrations to ensure it is deployed fairly across the UK. Health and Social Care Secretary Matt Hancock said:
Nearly 1.5 million people in the UK have already been vaccinated with the Pfizer/BioNTech and Oxford University/AstraZeneca vaccines, with more than 1,000 vaccination sites live by the end of the week across the UK to rapidly scale up the vaccination programme. The Joint Committee on Vaccination and Immunisation (JCVI) will submit updated advice on which groups to prioritise for vaccination before doses become available. Business Secretary Alok Sharma said:
The NHS has decades of experience in rolling out successful widespread vaccination programmes and is putting into place extensive preparations for the roll-out of the Moderna vaccine ahead of the spring. The Moderna vaccine will be deployed through similar methods:
Vaccine Deployment Minister Nadhim Zahawi said:
Through the Vaccines Taskforce, the UK has secured early access to 367 million doses of 7 of the most promising vaccines so far. To date, the government has invested over £230 million into manufacturing a successful vaccine. In the Chancellor’s Spending Review, published on 25 November, it was announced that the government has made more than £6 billion available to develop and procure successful vaccines. Deputy Chief Medical Officer for England Professor Jonathan Van-Tam said:
Interim Chair of the government’s Vaccines Taskforce Clive Dix said:
Background informationThe Pfizer/BioNTech and Oxford/AstraZeneca vaccines are being rolled out to priority groups. The full prioritisation list can be found here and is as follows (in order of priority):
Vaccination will be managed by the health services in each nation:
Through the government’s Vaccines Taskforce, the UK has secured early access to 367 million doses of 7 of the most promising vaccine candidates, including:
UK vaccine manufacturingThe UK government invested £100 million to fund a state-of-the-art manufacturing innovation centre in Braintree, Essex, in collaboration with the Cell and Gene Therapy Catapult, to accelerate the mass production of a successful COVID-19 vaccine in the UK. Due to open in December 2021, the centre will have the capacity to produce millions of doses of vaccines each month, ensuring the UK has the capabilities to manufacture both vaccines and advanced medicines, including for emerging diseases, far into the future. The government has also provided £4.7 million funding to the Catapult to ensure that the UK has the best skills and expertise in vaccine manufacturing and advanced therapies. The government has created the UK’s first dedicated Vaccine Manufacturing and Innovation Centre (VMIC) and accelerated its development with £93 million of investment. This investment will rapidly accelerate the construction of the facility, enabling us to bring it online sooner. It will also have expanded capability for advanced vaccine process development, fill and finish and bulk manufacture. In addition, the facility’s capacity will be significantly increased to be able to respond to this pandemic. Once open, it will be able to manufacture 70 million vaccines doses in just 6 months – enough for the UK population. Located in Oxfordshire, the centre will be the UK’s first not-for-profit organisation established to develop and advance the mass production of vaccines. This will boost the UK’s long-term capacity against future viruses. While VMIC is being built, the government established a Rapid Deployment Facility with £8.75 million of investment to manufacture at scale. The government has made a multi-million-pound investment in a manufacturing facility in Scotland, creating a major UK vaccine facility and to support rapid scale-up if its candidate is successful. This unique facility will establish a permanent UK capability to manufacture inactivated viral vaccines – one of the most proven, widely used vaccine formats. It is one of few Biosafety Level 3 (BSL3) containment facilities in Europe and has the capacity to produce up to 200 million doses of COVID-19 viral vaccines in 2021.
Published 8 January 2021
|
URL | 查看原文 |
来源平台 | Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/309997 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | admin. Moderna COVID-19 vaccine authorised by UK medicines regulator. 2021. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论